Previous close | 9.70 |
Open | 9.90 |
Bid | 10.00 |
Ask | 11.30 |
Strike | 85.00 |
Expiry date | 2025-03-21 |
Day's range | 9.58 - 10.00 |
Contract range | N/A |
Volume | |
Open interest | 168 |
The Committee for Medicinal Products for Human Use recommends marketing authorization for Moderna's updated mRNA COVID-19 jab, Spikevax.
Despite becoming one a household name during the pandemic, Moderna stock has mostly fallen over the past three years amid slow sales.
The FDA authorization for NVAX's updated COVID-19 vaccine makes it the only non-mRNA vaccine option in the country.